Rationale for Polyclonal Intravenous Immunoglobulin Adjunctive Therapy in COVID-19 Patients: Report of a Structured Multidisciplinary Consensus
Coloretti, I.; Berlot, G.; Busani, S.; De Rosa, F.G.; Donati, A.; Forfori, F.; Grasselli, G.; Mirabella, L.; Tascini, C.; Viale, P.; Girardis, M. Rationale for Polyclonal Intravenous Immunoglobulin Adjunctive Therapy in COVID-19 Patients: Report of a Structured Multidisciplinary Consensus. J. Clin. Med. 2021, 10, 3500. https://doi.org/10.3390/jcm10163500
Coloretti I, Berlot G, Busani S, De Rosa FG, Donati A, Forfori F, Grasselli G, Mirabella L, Tascini C, Viale P, Girardis M. Rationale for Polyclonal Intravenous Immunoglobulin Adjunctive Therapy in COVID-19 Patients: Report of a Structured Multidisciplinary Consensus. Journal of Clinical Medicine. 2021; 10(16):3500. https://doi.org/10.3390/jcm10163500
Chicago/Turabian StyleColoretti, Irene, Giorgio Berlot, Stefano Busani, Francesco G. De Rosa, Abele Donati, Francesco Forfori, Giacomo Grasselli, Lucia Mirabella, Carlo Tascini, Pierluigi Viale, and Massimo Girardis. 2021. "Rationale for Polyclonal Intravenous Immunoglobulin Adjunctive Therapy in COVID-19 Patients: Report of a Structured Multidisciplinary Consensus" Journal of Clinical Medicine 10, no. 16: 3500. https://doi.org/10.3390/jcm10163500